Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ISIS-14803 (Isis Pharmaceuticals).

G W Witherell1

  • 1Questor Pharmaceuticals Inc, Union City, CA 94587, USA. gwitherell@questcor.com

Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
PubMed
Summary

Isis and Merck are developing ISIS-14803, an antisense oligonucleotide, for hepatitis C virus (HCV) infection. Early trials show promise, leading to plans for combination studies and further evaluation of long-term dosing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response.

Journal of medical virology·2000
Same author

Cis-acting elements of the encephalomyocarditis virus internal ribosomal entry site.

Virology·1995
Same author

Encephalomyocarditis virus internal ribosomal entry site RNA-protein interactions.

Journal of virology·1994
Same author

Interaction of polypyrimidine tract binding protein with the encephalomyocarditis virus mRNA internal ribosomal entry site.

Biochemistry·1993
Same author

A cytoplasmic 57-kDa protein that is required for translation of picornavirus RNA by internal ribosomal entry is identical to the nuclear pyrimidine tract-binding protein.

Proceedings of the National Academy of Sciences of the United States of America·1993
Same author

Specific interaction between RNA phage coat proteins and RNA.

Progress in nucleic acid research and molecular biology·1991

Area of Science:

  • Hepatology
  • Antisense Oligonucleotide Therapeutics
  • Virology

Background:

  • Hepatitis C virus (HCV) infection remains a significant global health concern.
  • Antisense oligonucleotide (ASO) technology offers a novel therapeutic approach for viral infections.

Purpose of the Study:

  • To evaluate the potential of ISIS-14803, an antisense oligonucleotide, as a treatment for hepatitis C virus (HCV) infection.
  • To explore the efficacy of ISIS-14803 as a single agent and in combination with standard therapies.

Main Methods:

  • Phase I/II clinical trial of ISIS-14803.
  • Administration via intravenous (i.v.) infusions.
  • Evaluation of single-agent and combination therapy regimens.

Main Results:

  • ISIS-14803 demonstrated potential in early-phase trials.
  • Positive results prompted further development and combination studies.
  • Merck made a $1.5 million milestone payment for collaborative progress.

Conclusions:

  • ISIS-14803 is a promising candidate for HCV treatment.
  • Further clinical trials are planned to assess combination therapies and long-term efficacy.
  • The collaboration between Isis and Merck is advancing HCV therapeutic development.

Related Experiment Videos